|
Merck & Co., Inc. announced the trademark JANUMET™ for MK-0431A,
the Company's investigational oral medicine combining sitagliptin phosphate
with metformin for type 2 diabetes. JANUMET is designed to provide an additional
treatment option for patients who need more than one oral agent to help control
their blood sugar and is currently under standard review by the U.S. Food and
Drug Administration (FDA). Merck expects FDA action on the New Drug Application
(NDA) by the end of March 2007.
Data supporting JANUMET were previously disclosed earlier this year. Data
presented at the ADA included a 24-week, double-blind study of patients who
had inadequate glycemic control with metformin (at least 1,500 mg daily). In
this study, sitagliptin phosphate 100 mg once daily added to patients inadequately
controlled on metformin led to a significant additional mean reduction in A1C
of 0.7 percent compared with placebo (p<0.001). The concurrent administration
of sitagliptin phosphate with metformin was generally well tolerated, with no
increased incidence of hypoglycemia or gastrointestinal adverse events compared
with the placebo arm of the study. Body weight changes were similar between
the treatment groups.
Data presented at the EASD meeting demonstrated a significant mean placebo-subtracted
reduction in A1C of 2.1 percent from a mean baseline A1C of 8.8 percent (primary
analysis of all patients treated, p<0.001) with sitagliptin phosphate 50
mg twice daily and metformin 1,000 mg twice daily in patients as initial therapy.
This study included another arm with sitagliptin phosphate and a lower dose
of metformin and also monotherapy and placebo arms. Full results from this study
for JANUMET plus other data supporting sitagliptin phosphate will be presented
this week at the 19th World Diabetes Congress in Cape Town, South Africa.
In the study presented at EASD, simultaneous treatment with sitagliptin phosphate
and metformin was generally well tolerated and showed no meaningful differences
in tolerability compared to metformin alone. Side effects of simultaneous treatment
with sitagliptin phosphate 50 mg twice daily and metformin 1,000 mg twice daily
compared to metformin 1,000 mg twice daily alone included diarrhea (9 percent
vs. 10 percent, respectively), nausea (6 percent vs. 8 percent, respectively),
abdominal pain/discomfort (3 percent vs. 5 percent, respectively) and vomiting
(3 percent vs. 1 percent, respectively).
==========================
Advertisement
Multivitamin Supplements & Diabetes:
Recent research confirmed that taking a daily multivitamin and mineral supplement
has a positive impact on the quality of life for people with diabetes. So regularly
taking a multiple is an easy choice, but for most finding the right one to trust
with their health proves to be a more difficult matter. alpha betic(r) is uniquely
balanced to meet the special dietary needs of people with diabetes and those
predisposed to diabetes. alpha betic(r) contains 23 important nutrients in safe
and balanced doses, with no copper. For more information: Click Here
http://www.diabetesincontrool.com/ads/alphabetic/dest.php
|
Entries (RSS News)
